CSL (CSLLY) Receivables Turnover : 3.19 (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is CSL Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. CSL's Revenue for the six months ended in Dec. 2023 was $7,804 Mil. CSL's average Accounts Receivable for the six months ended in Dec. 2023 was $2,449 Mil. Hence, CSL's Receivables Turnover for the six months ended in Dec. 2023 was 3.19.

CSL Receivables Turnover Historical Data

The historical data trend for CSL's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Receivables Turnover Chart

CSL Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Receivables Turnover

Get a 7-Day Free Trial

7.12

7.60

9.69

10.69

11.03

CSL Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Receivables Turnover	Get a 7-Day Free Trial															3.59	2.92	3.50	2.82	3.19

Competitive Comparison of CSL's Receivables Turnover

For the Biotechnology subindustry, CSL's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSL's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where CSL's Receivables Turnover falls into.

CSL Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

CSL's Receivables Turnover for the fiscal year that ended in Jun. 2023 is calculated as

	Receivables Turnover (A: Jun. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Jun. 2023 )	/ (	(Accounts Receivable (A: Jun. 2022 )	+	Accounts Receivable (A: Jun. 2023 ))	/	count )
=	13174	/ (	(965.8	+	1424)	/	2 )
=	13174	/	1194.9
=	11.03

CSL's Receivables Turnover for the quarter that ended in Dec. 2023 is calculated as

	Receivables Turnover (Q: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2023 )	/ (	(Accounts Receivable (Q: Jun. 2023 )	+	Accounts Receivable (Q: Dec. 2023 ))	/	count )
=	7804	/ (	(1424	+	3473)	/	2 )
=	7804	/	2448.5
=	3.19

CSL (OTCPK:CSLLY) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

CSL Receivables Turnover Related Terms

Thank you for viewing the detailed overview of CSL's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

CSL (CSLLY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CSLLY) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

CMXHF:USA CSJ:Germany CSL:Australia

Address

655 Elizabeth Street, Melbourne, VIC, AUS, 3000

Website

https://www.csl.com

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.